Deerfield Management Company, L.P. (Series C) Janux Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.84 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$20.7 - $34.69 $14.5 Million - $24.3 Million	-700,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.58 - $25.37 $13 Million - $17.8 Million	700,000 New	700,000 $17.5 Million

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

Orbimed Advisors LLC San Diego, CA

4.28M
Shares

$179 Million
3.62% of portfolio
Bvf Inc San Francisco, CA

2.92M
Shares

$122 Million
3.29% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.78M
Shares

$116 Million
0.2% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.35M
Shares

$98.5 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

1.97M
Shares

$82.3 Million
0.04% of portfolio

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account